Metraipolis › archive › dc_dd4cf1ef30dc

Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC — Europe PMC PMID:42761382

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42761382
DOI
10.1016/j.gendis.2026.102230
License (as archived)
solo-consultazione
Archived
2026-11-02T10:12:12.563Z
SHA-256 of the archived text
d52ada1c8ad4c05a00fd11392d2e06a0c91b120e315cbacd6d5a2da280374e12
Stable URL of this page
https://metraipolis.com/documento/dc_dd4cf1ef30dc

How to cite

Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC — Europe PMC PMID:42761382 — Europe PMC (en), https://europepmc.org/article/MED/42761382 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dd4cf1ef30dc (Metraipolis archive dc_dd4cf1ef30dc, sha256 d52ada1c8ad4c05a00fd11392d2e06a0c91b120e315cbacd6d5a2da280374e12)
BibTeX
@misc{dcdd4cf1ef30dc,
  title = {Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC — Europe PMC PMID:42761382},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42761382},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dd4cf1ef30dc; sha256 d52ada1c8ad4c05a00fd11392d2e06a0c91b120e315cbacd6d5a2da280374e12},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42761382. Agents can read the archived copy with the MCP tool read_document.